Moderna (MRNA) and Merck (MRK) announce 5yr data for Intismeran in combination with Keytruda

• In this pre-planned analysis, adjuvant treatment with intismeran autogene in combination with Keytruda continued to demonstrate sustained and clinically meaningful improvement in the study's primary endpoint, recurrence-free survival, RFS, reducing the risk of recurrence or death by 49% compared to KEYTRUDA alone.

The announcement of sustained improvement in recurrence-free survival (RFS) from the combination treatment of Intismeran and Keytruda is significant for both Moderna and Merck. It suggests a strong therapeutic benefit that could bolster market confidence in their product offerings, potentially influencing stock performance positively and prompting investor interest in the biotech sector.